Journal ArticleOPEN ACCESS

Evaluation of Ofatumumab, a Novel Human CD20 Monoclonal Antibody, as Single Agent Therapy in Rituximab-Refractory Follicular Lymphoma.

  • Hagenbeek A
  • Fayad L
  • Delwail V
  • et al.
Blood (2009) 114(22) 935-935
DOI: 10.1182/blood.v114.22.935.935
N/ACitations
Citations of this article
7Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Abstract 935

Cite

CITATION STYLE

APA

Hagenbeek, A., Fayad, L., Delwail, V., Rossi, J. F., Jacobsen, E., Kuliczkowski, K., … Czuczman, M. S. (2009). Evaluation of Ofatumumab, a Novel Human CD20 Monoclonal Antibody, as Single Agent Therapy in Rituximab-Refractory Follicular Lymphoma. Blood, 114(22), 935–935. https://doi.org/10.1182/blood.v114.22.935.935

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free